Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring

Table 3 Comparison of selected pharmacokinetic parameters (median values) with rivaroxaban in specific patient populations

Population and rivaroxaban dose	C_max, ng/ml	C_trough, ng/ml	AUC, ng · h/ml	V_d/F, l	Interindividual variability in V_d, %CV	CL/F, l/h	Interindividual variability in CL/F, %CV
Hip surgery patients, 2.5–10 mg bid; 10 mg od	125* [11]	9* [11]	1170^†[11]	58 [11]	32 [11]	5–8 [11]	38 [11]
Patients treated for DVT; 10 mg bid, 20 and 30 mg od or bid, or 40 mg od	270 [12]	25^‡[12]	2870 [12]	54 [12]	29 [12]	6 [12]	40 [12]
Patients with AF; 15 and 20 mg od	257^‡ [Girgis. Unpublished data]	32 [12]	3466^† [Girgis. Unpublished data]	80 [Girgis. Unpublished data]	18 [Girgis. Unpublished data]	6 [Girgis. Unpublished data]	35 [Girgis. Unpublished data]
Patients with ACS; 2.5 mg bid	44^§[86]	16^§[86]	361^§[86]	58 [86]	10 [86]	6.5 [86]	31 [86]

*10 mg od.
^†AUC over a 24-hour period at steady-state.
^‡20 mg od at steady-state.
^§2.5 mg bid at steady-state; AUC over a 12-hour period.
Values rounded to nearest integer.
AF atrial fibrillation, AUC area under the concentration–time curve, bid twice daily, C_max maximum plasma concentration, C_trough steady-state trough concentration, CL/F apparent clearance, CV coefficient of variance, DVT deep vein thrombosis, NR not reported, od once daily, V_d/F volume of distribution at steady state.